Management

Ehud Marom, Chairman & CEO

Ehud Marom is one of our founders and has served as our chief executive officer and as chairman of our board of directors since our inception in January 2008. Mr. Marom has over 40 years of management and operational experience in the life sciences industry. Prior to our founding, Mr. Marom served in various senior positions at multinational pharmaceutical companies, including as vice president of two divisions at Teva Pharmaceutical Industries Ltd. from 1992 to 1995, where he launched Copaxone (with current sales of $4 billion per year) and was the head of the Copaxone global operation team and headed the global operations of Teva Pharmaceutical Industries Ltd.’s chemical division. From 2000 to 2002, Mr. Marom served as president of Peptor Ltd., where he led the pharmaceutical development of the innovative diabetes product, DiaPep. From 2002 to 2004, Mr. Marom served as chief executive officer of Gamida-Cell Ltd., a stem cell development company. From 2005 to 2007, Mr. Marom served as chief executive officer of Makhteshim, a company with annual sales of $1 billion and the world’s leader in branded off-patent crop protection solutions (which later became Makhteshim-Agan Industries Ltd. and has since been acquired by China National Agrochemical Corporation, a subsidiary of China National Chemical Corporation). Mr. Marom served as vice president of supply of Makhteshim-Agan Industries Ltd. from 2005 to 2009. He currently serves also as the chairman of Pharma Two B and helped guide its product, P2B001 for the treatment of early diagnosed Parkinson disease, through a successful phase IIb pivotal trial expected to be registered via the 505(b)(2) regulatory pathway. Mr. Maron serves as well as chief executive officer and chairman of Stem Cell Medicine Ltd. Ehud has a B.Sc in chemical engineering with honors, from the Technion, Israel.

 

Uri Danon, Executive VP

Uri Danon has served as our executive vice president since October 2013. For an accumulated five years ending in 2012, Mr. Danon served as president and later as chief executive officer of BioCancell Therapeutics Inc. (TASE: BICL), a clinical stage anti-cancer drug development company. He also previously served as chief executive officer of Atox Bio Ltd., a clinical stage drug development company focused on the treatment of severe infections and served as the company’s chairman of the board of directors from 2009 until November 2013. He previously managed international projects for Teva Pharmaceutical Industries Ltd., including the development of Copaxone in solution in pre-filled syringes (which has current sales of approximately $4 billion per year), from 1994 to 2000, and was chief executive officer of Epigenesis, Ltd., a cell therapy development company, from 2001 to 2003. Mr. Danon holds an MBA in marketing from Bar Ilan University, Israel, and a B.Sc. in industrial engineering and management from Tel Aviv University, Israel.

 

Nir Bernstein, VP Finance

Nir Bernstein has served as our vice president of finance since September 2015. Mr. Bernstein served as our chief financial officer from November 2013 until September 2015. From October 2010 until October 2013, Mr. Bernstein served as vice president of accounting and controller of Ampal-American Israel Corp Inc., a public company (NASDAQ: AMPL) that acquires interests in businesses located or operating in Israel. From August 1997 until September 2010, Mr. Bernstein worked as a senior manager at PricewaterhouseCoopers, an international accounting firm. Mr. Bernstein holds a B.A. in management and accounting from the College of Management and a B.Sc. in physics from the Hebrew University of Jerusalem, Israel.

 

Shai Rubnov, PhD, VP R&D

Shai Rubnov has served as our vice president of research and development since 2009. From 2007 to 2009, Dr. Rubnov served as head of chemistry, manufacturing and control, quality assurance and regulatory affairs at Therapix Bioscience Ltd. (formerly NasVax Ltd.), an Israeli drug development company. From 2002 to 2007, Dr. Rubnov served as a director of chemistry, manufacturing and control at DeveloGen AG., a German-Israeli biotechnology company, where he gained extensive experience in investigational new drug development and medicinal chemistry. Dr. Rubnov holds a PhD in medicinal chemistry and a BPharm from the Hebrew University in Jerusalem, Israel. Dr. Rubnov has completed his post-doctoral training at the French National Center for Scientific Research in Paris.

 

Alex Mogle, VP Corporate Development

Alex Mogle has served as our vice president of corporate development since June 2012. Mr. Mogle has over 15 years of executive experience in the life science and chemical industries. From 2003 until 2012, Mr. Mogle served in several capacities, including company secretary, investor relations director and as the head of the supply chain of Makhteshim Agan Industries Ltd., and was responsible for sales planning and inventory management which is valued at over $1 billion. Prior to Makhteshim Agan Industries Ltd., Mr. Mogle served as business development manager of the digital video division of Nice Systems Ltd., and as an economist in the Israeli Ministry of Finance. Mr. Mogle has a B.A., with honors, in economics and an MBA, majoring in finance and accounting, both from the Hebrew University of Jerusalem, Israel.

 

Laura Popper, MD, Medical Director

Laura Popper has served as our Medical Director since September 2016. Dr. Popper brings with her over 11 years of experience in Pharma and Biotech. Prior to joining Mapi, from 2004 through 2016, Dr. Popper served in senior positions in some of the world’s leading pharmaceutical companies, covering a vast arena of therapeutic areas. She most recently served as the Medical Affairs Manager in Astellas (TYO: 4503), following four years as Medical Manager at Sanofi, and, previously, as the Medical Advisor and Pharmacovigilance Country Head in Bayer. Dr. Popper started her career in the pharmaceutical industry as the Clinical Director at Foamix (Nasdaq: FOMX). Dr. Popper holds an M.D. from the University of Buenos Aires, and a post-doctorate in Neurobiology from the Weizmann Institute of Science. Dr. Popper is a pediatrician by training; she completed an internship in medicine and a residency in pediatrics and served as a teaching assistant to the Pharmacology and the Biochemistry Chairs at the University of Buenos Aires.

 

Nadav Bleich Kimelman, DMD, PhD, Director, Clinical Operations

Nadav Bleich Kimelman has served as our director of clinical operations since 2017. Dr. Bleich Kimelman joined Mapi Pharma in 2012 to serve as depot formulation team leader, and from 2014, he served as manager of depot products. In those capacities, Dr. Bleich Kimelman was responsible for the Company’s Depot Formulations line production development and scale-up. Additionally, Dr. Bleich Kimelman managed the pre-clinical as well as the clinical studies for this product line. Dr. Bleich Kimelman graduated from the DMD-PhD program at the Hebrew University of Jerusalem, Israel. He is a certified Doctor of Dental Medicine and was awarded for Excellent PhD thesis.